C-Src binds to the cancer drug Ruxolitinib with an active conformation

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Duan, Yankun ^a   Chen, Lin ^a,b   Chen, Yongheng ^a,b   Fan, Xue Gong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ASPARTYLPHENYLALANYLGLYCINE; JANUS KINASE 1; METHIONINE; PROTEIN TYROSINE KINASE; RUXOLITINIB; THREONINE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; PROTEIN BINDING; PROTEIN KINASE P60; PYRAZOLE DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN MOTIF; SEQUENCE ALIGNMENT; BINDING SITE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BINDING SITES; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEIN PP60(V-SRC); PROTEIN BINDING; PYRAZOLES; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84907082111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106225     Document Type: Article

References (33)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The Protein Kinase Complement of the Human Genome. Science 298: 1912-1934.
2. Hanahan D, Weinberg Robert A (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
3. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
4. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502.
5. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotech 29: 1046-1051.
6. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. (2002) Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571). Cancer Research 62: 4236-4243.
7. Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, et al. (2007) c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15: 299-311.
8. Jacobs MD, Caron PR, Hare BJ (2008) Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: Structure of lck/imatinib complex. Proteins: Structure, Function, and Bioinformatics 70: 1451-1460.
9. Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, et al. (2010) Analysis of Imatinib and Sorafenib Binding to p38α Compared with c-Abl and b-Raf Provides Structural Insights for Understanding the Selectivity of Inhibitors Targeting the DFG-Out Form of Protein Kinases. Biochemistry 49: 3611-3618.
10. Ghose AK, Herbertz T, Pippin DA, Salvino JM, Mallamo JP (2008) Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery. Journal of Medicinal Chemistry 51: 5149-5171.
11. Kufareva I, Abagyan R (2008) Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States. Journal of Medicinal Chemistry 51: 7921-7932.
12. Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2: 358-364.
13. Zuccotto F, Ardini E, Casale E, Angiolini M (2009) Through the "Gatekeeper Door": Exploiting the Active Kinase Conformation. Journal of Medicinal Chemistry 53: 2681-2694.
14. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15: 1109-1118.
15. Bikker JA, Brooijmans N, Wissner A, Mansour TS (2009) Kinase domain mutations in cancer: implications for small molecule drug design strategies. J Med Chem 52: 1493-1509.
16. Soverini S (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on Chronic Myeloid Leukemia. Clin Cancer Res 12: 7374-7379.
17. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. (2010) Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New England Journal of Medicine 363: 1117-1127.
18. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, et al. (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109-3117.
19. Zhou T, Georgeon S, Moser R, Moore DJ, Caflisch A, et al. (2014) Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia 28: 404-407.
20. Mascarenhas J, Hoffman R (2012) Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis. Clinical Cancer Research 18: 3008-3014.
21. Seeliger MA (2005) High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci 14: 3135-3139.
22. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307-326.
23. Chen Y, Bates Darren L, Dey R, Chen P-H, Machado Ana Carolina D, et al. (2012) DNA Binding by GATA Transcription Factor Suggests Mechanisms of DNA Looping and Long-Range Gene Regulation. Cell Reports 2: 1197-1206.
24. Chen Y, Zhang X, Dantas Machado AC, Ding Y, Chen Z, et al. (2013) Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion. Nucleic Acids Research 41: 8368-8376.
25. CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763.
26. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC (1999) Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3: 629-638.
27. Adams PD (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58: 1948-1954.
28. Abagyan R, Totrov M, Kuznetsov D (1994) ICM - A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. Journal of Computational Chemistry 15: 488-506.
29. Williams NK, Bamert RS, Patel O, Wang C, Walden PM, et al. (2009) Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains. Journal of Molecular Biology 387: 219-232.
30. Yu J, Zhou Y, Tanaka I, Yao M (2010) Roll: a new algorithm for the detection of protein pockets and cavities with a rolling probe sphere. Bioinformatics 26: 46-52.
31. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Engineering 8: 127-134.
32. Treiber Daniel K, Shah Neil P (2013) Ins and Outs of Kinase DFG Motifs. Chemistry & Biology 20: 745-746.
33. Seeliger MA (2007) c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15: 299-311.